Health & Fitness:Medicine
Top Metastatic Breast Cancer Research at ASCO 2019
2019-06-14
Download
Right click and do "save link as"
Dr. Maura Dickler, vice president of oncology late phase development for Eli Lilly and Company, offers insights on some of the most interesting research on metastatic breast cancer presented at the 2019 American Society of Clinical Oncology Annual Meeting.
Listen to the podcast to hear Dr. Dickler explain:
- results from the IMpassion 130 trial looking at Tecentriq (chemical name: atezolizumab) and Abraxane (chemical name: albumin-bound or nab-paclitaxel) to treat metastatic triple-negative breast cancer
- results from the Young-PEARL trial studying Ibrance (chemical name: palbociclib) and Aromasin (chemical name: exemestane) along with ovarian suppression to treat premenopausal women diagnosed with hormone-receptor-positive metastatic breast cancer overall survival
- results from the MONALEESA-7 trial, which examined using Kisqali (chemical name: ribociclib) and hormonal therapy to treat premenopausal women diagnosed with hormone-receptor-positive, HER2-negative advanced-stage breast cancer
More Episodes
Oral Side Effects of Breast Cancer Treatment
2024-09-27
2024-09-27
The Mastectomy I Always Wanted
2024-09-13
2024-09-13
Summer 2024 Breast Cancer Research Round Up
2024-08-30
2024-08-30
Osteoporosis and Breast Cancer
2024-08-16
2024-08-16
Podcasting From the Chemo Chair
2024-08-09
2024-08-09
Bias in Healthcare AI
2024-07-16
2024-07-16
Research on Side Effects at ASCO 2024
2024-06-21
2024-06-21
Top Breast Cancer Research at ASCO 2024
2024-06-04
2024-06-04
Genetic Testing Saved My Life
2024-06-04
2024-06-04
The Boob Bus
2024-05-24
2024-05-24
How to Ease Stress
2024-04-12
2024-04-12
Nutrition and Breast Cancer
2024-03-22
2024-03-22
Get this podcast on your
phone, FREE
